What Analysts Are Saying About Alcon Stock
Benzinga Insights 8 months ago
Analyst Ratings
In the latest quarter, 7 analysts provided ratings for Alcon (NYSE:ALC), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 3 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 1 | 0 |
Analysts have set 12-month price targets for Alcon, revealing an average target of $88.0, a high estimate of $100.00, and a low estimate of $75.00. Observing a downward trend, the current average is 1.91% lower than the prior average price target of $89.71.
Breaking Down Analyst Ratings: A Detailed Examination
The analysis of recent analyst actions sheds light on the perception of Alcon by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Stephan | Stifel | Raises | Hold | $82.00 | $80.00 |
| Matt Miksic | Barclays | Raises | Equal-Weight | $90.00 | $86.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $97.00 | $88.00 |
| David Saxon | Needham | Raises | Buy | $100.00 | $98.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $92.00 | $91.00 |
| Thomas Stephan | Stifel | Lowers | Hold | $80.00 | $85.00 |
| Julien Ouaddour | B of A Securities | Lowers | Underperform | $75.00 | $100.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Alcon. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alcon compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Alcon's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Alcon's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Alcon analyst ratings.
Unveiling the Story Behind Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Understanding the Numbers: Alcon's Finances
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Alcon's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2025, the company achieved a revenue growth rate of approximately 8.63%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alcon's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.99%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Alcon's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.